Palonosetron View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2004-05

AUTHORS

M. Asif A. Siddiqui, Lesley J. Scott

ABSTRACT

Palonosetron is a potent and highly selective serotonin 5-HT(3) receptor antagonist that has been evaluated for the prevention of chemotherapy-induced nausea and vomiting. black triangle Intravenously administered palonosetron has a linear pharmacokinetic profile, with a long terminal elimination half-life ( approximate, equals 40 hours) and moderate (62%) plasma protein binding. In two randomised, double-blind trials in 1132 cancer patients receiving moderately emetogenic chemotherapy, intravenous palonosetron 0.25 mg was more effective than intravenous ondansetron 32 mg in producing a complete response (no emesis, no use of rescue medication) during acute (0-24 hours) or delayed (24-120 hours) phases, and similar to intravenous dolasetron 100 mg in acute, but more effective in delayed phase. Palonosetron 0.75 mg was similar to ondansetron (acute and delayed phase) or dolasetron (acute phase), but more effective than dolasetron in delayed phase. In patients receiving highly emetogenic chemotherapy (n = 667), the complete response rates during acute and delayed phases with intravenous palonosetron (0.25 or 0.75 mg) were similar to those seen in intravenous ondansetron 32 mg recipients in a randomised, double-blind trial. Intravenous palonosetron was generally well tolerated in clinical trials, with few adverse events being treatment related. Palonosetron had no significant effect on the corrected QT interval or laboratory parameters. More... »

PAGES

1125-1132

Identifiers

URI

http://scigraph.springernature.com/pub.10.2165/00003495-200464100-00006

DOI

http://dx.doi.org/10.2165/00003495-200464100-00006

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1037955349

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/15139789


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antiemetics", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Injections, Intravenous", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Isoquinolines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Nausea", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Palonosetron", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quinuclidines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Randomized Controlled Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Serotonin 5-HT3 Receptor Antagonists", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vomiting", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Springer (New Zealand)", 
          "id": "https://www.grid.ac/institutes/grid.420067.7", 
          "name": [
            "Adis International Limited, 41 Centorian Drive, Private Bag 65901, 1311, Mairangi Bay, Auckland, New Zealand"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Siddiqui", 
        "givenName": "M. Asif A.", 
        "id": "sg:person.01303054417.19", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01303054417.19"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Springer (New Zealand)", 
          "id": "https://www.grid.ac/institutes/grid.420067.7", 
          "name": [
            "Adis International Limited, 41 Centorian Drive, Private Bag 65901, 1311, Mairangi Bay, Auckland, New Zealand"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Scott", 
        "givenName": "Lesley J.", 
        "id": "sg:person.01244653776.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01244653776.31"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1002/cncr.11817", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010335838"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003495-198300251-00002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021192528", 
          "https://doi.org/10.2165/00003495-198300251-00002"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdh047", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026990645"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1476-5381.1995.tb13283.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031465223"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003495-199652050-00002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037308623", 
          "https://doi.org/10.2165/00003495-199652050-00002"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0959-8049(98)00417-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038757244"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0277-5379(83)90418-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042962166"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1997.507", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043604506", 
          "https://doi.org/10.1038/bjc.1997.507"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1997.507", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043604506", 
          "https://doi.org/10.1038/bjc.1997.507"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdg417", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047729604"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1476-5381.1995.tb13282.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050303878"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074458360", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/ajhp/56.8.729", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074458360"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/ajhp/56.8.729", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074458360"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/ajhp/56.8.729", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074458360"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1999.17.9.2971", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074549933"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2004-05", 
    "datePublishedReg": "2004-05-01", 
    "description": "Palonosetron is a potent and highly selective serotonin 5-HT(3) receptor antagonist that has been evaluated for the prevention of chemotherapy-induced nausea and vomiting. black triangle Intravenously administered palonosetron has a linear pharmacokinetic profile, with a long terminal elimination half-life ( approximate, equals 40 hours) and moderate (62%) plasma protein binding. In two randomised, double-blind trials in 1132 cancer patients receiving moderately emetogenic chemotherapy, intravenous palonosetron 0.25 mg was more effective than intravenous ondansetron 32 mg in producing a complete response (no emesis, no use of rescue medication) during acute (0-24 hours) or delayed (24-120 hours) phases, and similar to intravenous dolasetron 100 mg in acute, but more effective in delayed phase. Palonosetron 0.75 mg was similar to ondansetron (acute and delayed phase) or dolasetron (acute phase), but more effective than dolasetron in delayed phase. In patients receiving highly emetogenic chemotherapy (n = 667), the complete response rates during acute and delayed phases with intravenous palonosetron (0.25 or 0.75 mg) were similar to those seen in intravenous ondansetron 32 mg recipients in a randomised, double-blind trial. Intravenous palonosetron was generally well tolerated in clinical trials, with few adverse events being treatment related. Palonosetron had no significant effect on the corrected QT interval or laboratory parameters.", 
    "genre": "research_article", 
    "id": "sg:pub.10.2165/00003495-200464100-00006", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1084788", 
        "issn": [
          "0012-6667", 
          "1179-1950"
        ], 
        "name": "Drugs", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "10", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "64"
      }
    ], 
    "name": "Palonosetron", 
    "pagination": "1125-1132", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "b4ce7f73c113f8646b6074566abd584e878929ee062fc2678e423426c1d5c6a7"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "15139789"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "7600076"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.2165/00003495-200464100-00006"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1037955349"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.2165/00003495-200464100-00006", 
      "https://app.dimensions.ai/details/publication/pub.1037955349"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T12:35", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000363_0000000363/records_70027_00000001.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.2165/00003495-200464100-00006"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.2165/00003495-200464100-00006'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.2165/00003495-200464100-00006'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.2165/00003495-200464100-00006'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.2165/00003495-200464100-00006'


 

This table displays all metadata directly associated to this object as RDF triples.

165 TRIPLES      21 PREDICATES      54 URIs      33 LITERALS      21 BLANK NODES

Subject Predicate Object
1 sg:pub.10.2165/00003495-200464100-00006 schema:about N12a5399dbe934e1783ed1a1dce9dd205
2 N3c50571343fd4c1e9b9de069fa01bb81
3 N4d8ab3b19f4746deb5bdb126d5504c79
4 N702cb4eaf552443dbb6ebabe808fcb03
5 N8201f3dbe0884fe182a76138f02353d6
6 N91fa8cdce85b4739a818f63366b6ad8c
7 N93d52506491648e4b15e052520b4e96d
8 N961a23faa8d84cf890809fd93472c4bc
9 Nb4dbdb20dece4f409f02f266b71fa83e
10 Nd0dd12d90b944fafab8cb2eaaf376527
11 Ne15018eb62fa41cba1167dfc7a460125
12 Nfb7f0bb18c0642cf8ed2ae1f8c1adf95
13 anzsrc-for:11
14 anzsrc-for:1112
15 schema:author N7201be3ade324df989dab501be2099cf
16 schema:citation sg:pub.10.1038/bjc.1997.507
17 sg:pub.10.2165/00003495-198300251-00002
18 sg:pub.10.2165/00003495-199652050-00002
19 https://app.dimensions.ai/details/publication/pub.1074458360
20 https://doi.org/10.1002/cncr.11817
21 https://doi.org/10.1016/0277-5379(83)90418-2
22 https://doi.org/10.1016/s0959-8049(98)00417-1
23 https://doi.org/10.1093/ajhp/56.8.729
24 https://doi.org/10.1093/annonc/mdg417
25 https://doi.org/10.1093/annonc/mdh047
26 https://doi.org/10.1111/j.1476-5381.1995.tb13282.x
27 https://doi.org/10.1111/j.1476-5381.1995.tb13283.x
28 https://doi.org/10.1200/jco.1999.17.9.2971
29 schema:datePublished 2004-05
30 schema:datePublishedReg 2004-05-01
31 schema:description Palonosetron is a potent and highly selective serotonin 5-HT(3) receptor antagonist that has been evaluated for the prevention of chemotherapy-induced nausea and vomiting. black triangle Intravenously administered palonosetron has a linear pharmacokinetic profile, with a long terminal elimination half-life ( approximate, equals 40 hours) and moderate (62%) plasma protein binding. In two randomised, double-blind trials in 1132 cancer patients receiving moderately emetogenic chemotherapy, intravenous palonosetron 0.25 mg was more effective than intravenous ondansetron 32 mg in producing a complete response (no emesis, no use of rescue medication) during acute (0-24 hours) or delayed (24-120 hours) phases, and similar to intravenous dolasetron 100 mg in acute, but more effective in delayed phase. Palonosetron 0.75 mg was similar to ondansetron (acute and delayed phase) or dolasetron (acute phase), but more effective than dolasetron in delayed phase. In patients receiving highly emetogenic chemotherapy (n = 667), the complete response rates during acute and delayed phases with intravenous palonosetron (0.25 or 0.75 mg) were similar to those seen in intravenous ondansetron 32 mg recipients in a randomised, double-blind trial. Intravenous palonosetron was generally well tolerated in clinical trials, with few adverse events being treatment related. Palonosetron had no significant effect on the corrected QT interval or laboratory parameters.
32 schema:genre research_article
33 schema:inLanguage en
34 schema:isAccessibleForFree false
35 schema:isPartOf N008011c740f44b9486908f580692dfe5
36 Ne5028a1908c34018a6da9aa1dbae721e
37 sg:journal.1084788
38 schema:name Palonosetron
39 schema:pagination 1125-1132
40 schema:productId N61658befb38341fc97296e96ad445815
41 N92074353c12b4f8794a213cf4a04870d
42 Nb527401132a648f9962da4b2e66fd4e3
43 Ncfcede1e69954a5ea6684dc3bdec1d1c
44 Nf0e0ff8a6f194b27898d804d99d8492b
45 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037955349
46 https://doi.org/10.2165/00003495-200464100-00006
47 schema:sdDatePublished 2019-04-11T12:35
48 schema:sdLicense https://scigraph.springernature.com/explorer/license/
49 schema:sdPublisher Nca9600d88330437d897828933a9bc00b
50 schema:url http://link.springer.com/10.2165/00003495-200464100-00006
51 sgo:license sg:explorer/license/
52 sgo:sdDataset articles
53 rdf:type schema:ScholarlyArticle
54 N008011c740f44b9486908f580692dfe5 schema:issueNumber 10
55 rdf:type schema:PublicationIssue
56 N12a5399dbe934e1783ed1a1dce9dd205 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
57 schema:name Quinuclidines
58 rdf:type schema:DefinedTerm
59 N3c50571343fd4c1e9b9de069fa01bb81 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
60 schema:name Injections, Intravenous
61 rdf:type schema:DefinedTerm
62 N4d8ab3b19f4746deb5bdb126d5504c79 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
63 schema:name Neoplasms
64 rdf:type schema:DefinedTerm
65 N61658befb38341fc97296e96ad445815 schema:name nlm_unique_id
66 schema:value 7600076
67 rdf:type schema:PropertyValue
68 N702cb4eaf552443dbb6ebabe808fcb03 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
69 schema:name Nausea
70 rdf:type schema:DefinedTerm
71 N7201be3ade324df989dab501be2099cf rdf:first sg:person.01303054417.19
72 rdf:rest Nd15e2b0c6857406d999b9e5fb7f90aea
73 N8201f3dbe0884fe182a76138f02353d6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
74 schema:name Randomized Controlled Trials as Topic
75 rdf:type schema:DefinedTerm
76 N91fa8cdce85b4739a818f63366b6ad8c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
77 schema:name Antineoplastic Agents
78 rdf:type schema:DefinedTerm
79 N92074353c12b4f8794a213cf4a04870d schema:name dimensions_id
80 schema:value pub.1037955349
81 rdf:type schema:PropertyValue
82 N93d52506491648e4b15e052520b4e96d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
83 schema:name Isoquinolines
84 rdf:type schema:DefinedTerm
85 N961a23faa8d84cf890809fd93472c4bc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
86 schema:name Antiemetics
87 rdf:type schema:DefinedTerm
88 Nb4dbdb20dece4f409f02f266b71fa83e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
89 schema:name Humans
90 rdf:type schema:DefinedTerm
91 Nb527401132a648f9962da4b2e66fd4e3 schema:name readcube_id
92 schema:value b4ce7f73c113f8646b6074566abd584e878929ee062fc2678e423426c1d5c6a7
93 rdf:type schema:PropertyValue
94 Nca9600d88330437d897828933a9bc00b schema:name Springer Nature - SN SciGraph project
95 rdf:type schema:Organization
96 Ncfcede1e69954a5ea6684dc3bdec1d1c schema:name pubmed_id
97 schema:value 15139789
98 rdf:type schema:PropertyValue
99 Nd0dd12d90b944fafab8cb2eaaf376527 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
100 schema:name Palonosetron
101 rdf:type schema:DefinedTerm
102 Nd15e2b0c6857406d999b9e5fb7f90aea rdf:first sg:person.01244653776.31
103 rdf:rest rdf:nil
104 Ne15018eb62fa41cba1167dfc7a460125 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Vomiting
106 rdf:type schema:DefinedTerm
107 Ne5028a1908c34018a6da9aa1dbae721e schema:volumeNumber 64
108 rdf:type schema:PublicationVolume
109 Nf0e0ff8a6f194b27898d804d99d8492b schema:name doi
110 schema:value 10.2165/00003495-200464100-00006
111 rdf:type schema:PropertyValue
112 Nfb7f0bb18c0642cf8ed2ae1f8c1adf95 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Serotonin 5-HT3 Receptor Antagonists
114 rdf:type schema:DefinedTerm
115 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
116 schema:name Medical and Health Sciences
117 rdf:type schema:DefinedTerm
118 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
119 schema:name Oncology and Carcinogenesis
120 rdf:type schema:DefinedTerm
121 sg:journal.1084788 schema:issn 0012-6667
122 1179-1950
123 schema:name Drugs
124 rdf:type schema:Periodical
125 sg:person.01244653776.31 schema:affiliation https://www.grid.ac/institutes/grid.420067.7
126 schema:familyName Scott
127 schema:givenName Lesley J.
128 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01244653776.31
129 rdf:type schema:Person
130 sg:person.01303054417.19 schema:affiliation https://www.grid.ac/institutes/grid.420067.7
131 schema:familyName Siddiqui
132 schema:givenName M. Asif A.
133 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01303054417.19
134 rdf:type schema:Person
135 sg:pub.10.1038/bjc.1997.507 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043604506
136 https://doi.org/10.1038/bjc.1997.507
137 rdf:type schema:CreativeWork
138 sg:pub.10.2165/00003495-198300251-00002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021192528
139 https://doi.org/10.2165/00003495-198300251-00002
140 rdf:type schema:CreativeWork
141 sg:pub.10.2165/00003495-199652050-00002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037308623
142 https://doi.org/10.2165/00003495-199652050-00002
143 rdf:type schema:CreativeWork
144 https://app.dimensions.ai/details/publication/pub.1074458360 schema:CreativeWork
145 https://doi.org/10.1002/cncr.11817 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010335838
146 rdf:type schema:CreativeWork
147 https://doi.org/10.1016/0277-5379(83)90418-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042962166
148 rdf:type schema:CreativeWork
149 https://doi.org/10.1016/s0959-8049(98)00417-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038757244
150 rdf:type schema:CreativeWork
151 https://doi.org/10.1093/ajhp/56.8.729 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074458360
152 rdf:type schema:CreativeWork
153 https://doi.org/10.1093/annonc/mdg417 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047729604
154 rdf:type schema:CreativeWork
155 https://doi.org/10.1093/annonc/mdh047 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026990645
156 rdf:type schema:CreativeWork
157 https://doi.org/10.1111/j.1476-5381.1995.tb13282.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1050303878
158 rdf:type schema:CreativeWork
159 https://doi.org/10.1111/j.1476-5381.1995.tb13283.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1031465223
160 rdf:type schema:CreativeWork
161 https://doi.org/10.1200/jco.1999.17.9.2971 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074549933
162 rdf:type schema:CreativeWork
163 https://www.grid.ac/institutes/grid.420067.7 schema:alternateName Springer (New Zealand)
164 schema:name Adis International Limited, 41 Centorian Drive, Private Bag 65901, 1311, Mairangi Bay, Auckland, New Zealand
165 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...